计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D337434-50mg |
50mg |
现货 ![]() |
| |
| D337434-250mg |
250mg |
现货 ![]() |
| |
| D337434-1g |
1g |
现货 ![]() |
|
| 别名 | (R/S)-1-[2-(二甲胺)-1-(4-甲氧苯基)乙基]环己醇 |
|---|---|
| 英文别名 | Wy 45030 | AB00053751_12 | Venlafaxina [INN-Spanish] | BRD-A51714012-003-01-1 | D08670 | NCGC00095109-01 | SDCCGSBI-0052740.P003 | WY-45655 | Effexor | FT-0675793 | N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine | NCGC00095109-06 | Spe |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | D,L-Venlafaxine |
| 储存温度 | 2-8°C储存 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | NET 抑制剂;SERT 抑制剂 |
| 产品介绍 |
D,L-文拉法辛是文拉法辛的异构体。文拉法辛是苯乙胺的衍生物,据报道可通过阻止神经胺如5-羟色胺(5-羟色胺; 5-HT)和去甲肾上腺素(去甲肾上腺素)的突触前再摄取来促进中枢神经系统内的神经传递。还报道了Velanfaxine是多巴胺再摄取的弱抑制剂。|体外研究表明,Venlafaxine对毒蕈碱,组胺能或α-1肾上腺素受体没有明显的活性。据报道,文拉法辛的代谢是通过细胞色素P450(CYP)酶CYP2D6发生的,产生O-去甲基文拉法辛。CYP3A4产生较少的代谢产物N-去甲基文拉法辛。 D,L-Venlafaxine is an isomer of Venlafaxine . Venlafaxine is a derivative of phenylethylamine which is reported to facilitate neurotransmission within the central nervous system via blocking the presynaptic reuptake of neuroamines such as serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine). Velanfaxine is also reported to be a weak inhibitor of dopamine reuptake.|In vitro|studies indicate that Venlafaxine does not demonstrate significant activity for muscarinic, histaminergic or α-1 adrenergic receptors. The metabolism of venlafaxine is reported to occur by cytochrome P450 (CYP) enzyme CYP2D6 yielding O-desmethylvenlafaxine. A lesser metabolite, N-desmethylvenlafaxine is produced by CYP3A4. |
| 纯度 | ≥98% |
| pKa值 | pKₐ: 9.27 (Predicted) |
|---|---|
| Ki Data | Norepinephrine transporter: Ki= 138 nM (rat); Serotonin transporter: Ki= 52 nM (rat); Dopamine transporter: Ki= 360 nM (rat) |
| IC50 | Serotonin transporter: IC₅₀= 35 nM (human); Alpha-1a adrenergIC₅₀eceptor: IC₅₀= 109 nM (rat); Dopamine transporter: IC₅₀= 7.34 μM (human); Norepinephrine transporter: IC₅₀= 535 nM (human) |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504750924 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol |
| INCHI | 1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3 |
| InChi Key | PNVNVHUZROJLTJ-UHFFFAOYSA-N |
| Smiles | CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O |
| Isomeric SMILES | CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O |
| 分子量 | 277.4 |
| Beilstein号 | 4234848 |
| Reaxy-Rn | 4234848 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4234848&ln= |
| 溶解性 | Soluble in dichloromethane, ethyl acetate, and methanol. |
|---|---|
| 密度 | 1.06 g/cm3(Predicted) |
| 折光率 | n20D1.54 (Predicted) |
| 沸点 | 397.58° C at 760 mmHg (Predicted) |
| 熔点 | 72-74° C (lit.) |
| 分子量 | 277.400 g/mol |
| XLogP3 | 2.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 277.204 Da |
| 单同位素质量Monoisotopic Mass | 277.204 Da |
| 拓扑极表面积Topological Polar Surface Area | 32.700 Ų |
| 重原子数Heavy Atom Count | 20 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 279.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07, GHS08, GHS09 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H302: 吞食有害 H319: 引起严重眼睛刺激 H360: 可能损害生育力或未出生的孩子 H362: 可能对母乳喂养的孩子造成伤害 H411: 对水生生物有毒并具有长期持续影响 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P263: 避免在怀孕期间/哺乳期间接触。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P330: 漱口 P391: 收集溢出物 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P318: 如果暴露或担心,请就医。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 |
| RTECS | GV8872620 |
| 1. Da Wang, Stefanos Giannakis, Jingyu Tang, Kai Luo, Juntao Tang, Zhiqiao He, Shuang Song, Lizhang Wang. (2023) Effect of rGO content on enhanced Photo-Fenton degradation of Venlafaxine using rGO encapsulated magnetic hexagonal FeTiO3 nanosheets. CHEMICAL ENGINEERING JOURNAL, 478 (147319). [10.1016/j.cej.2023.147319] |
| 2. Boping Yu, Qi Han, Chaolin Li, Yuying Zhu, Xingliang Jin, Zhiguang Dai. (2022) Influencing factors of venlafaxine degradation at boron-doped diamond anode. Arabian Journal of Chemistry, 15 (103463). [10.1016/j.arabjc.2021.103463] |
| 3. Lu Yang, Zijin Lin, Ruijing Mu, Wenhan Wu, Hao Zhi, Xiaodong Liu, Hanyu Yang, Li Liu. (2024) Neurons enhance blood–brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion. eLife, (2024 Oct). [PMID:39475379] [10.7554/eLife.96161] |